<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541631</url>
  </required_header>
  <id_info>
    <org_study_id>087540</org_study_id>
    <secondary_id>00005856/2011</secondary_id>
    <nct_id>NCT01541631</nct_id>
  </id_info>
  <brief_title>A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes</brief_title>
  <official_title>Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of Health and Allied Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of Health and Allied Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, it is hypothesized that helminth infections modulate immune responses against&#xD;
      HIV-1 infection resulting into increased HIV-1 multiplication, faster progression to AIDS and&#xD;
      increased episodes of AIDS-related opportunistic infections. Furthermore, the effect of&#xD;
      helminth infections on progression of HIV-1 infection is dependent on helminth infection&#xD;
      intensity, host background immunity, nutritional status, demographic factors and&#xD;
      socio-economic status. Also, treatment of helminth infections using praziquantel and&#xD;
      albendazole among HIV-1 infected individuals will lead to reduction in HIV-1 viral loads,&#xD;
      improvement of CD4+ counts, CD4+/CD8+ ratio and Hb levels, improved weight gain and reduction&#xD;
      of episodes of HIV-1 related opportunistic infections. In addition, HIV-1 infection is&#xD;
      associated with poor anthelminthic treatment outcome as compared to non-HIV infected&#xD;
      individuals&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study has the main objective to investigate the epidemiology of HIV-1 and&#xD;
      Schistosoma mansoni co-infections and assess their association and progress of HIV positive&#xD;
      individuals co-infected with S. mansoni. The study will also assess the impact of&#xD;
      praziquantel treatment on S. mansoni related morbidities in co-infected HIV positive&#xD;
      individuals with S. mansoni in Fishing villages, northwest Tanzania. The study is designed as&#xD;
      a community based intervention trial, which consist of cross-sectional survey at the initial&#xD;
      baseline survey followed by intervention trials. The initial baseline survey will include&#xD;
      2000 participants from the two villages. The objective of the survey is to determine the&#xD;
      prevalence of HIV-1 infection and haemoglobin levels. Also, the socio-economic, demographic&#xD;
      characteristics, individual behaviour in relation to HIV-1 and helminth transmission are&#xD;
      recorded. In addition, the location and altitude of each household will determined using a&#xD;
      hand-held Garmin GPSmap 60CSX, which has an accuracy of Â± 5m. After initial survey, study&#xD;
      participant will be grouped into 2 groups, one HIV-1 infected group and HIV-1 uninfected&#xD;
      group. Blood sample for examination of CD4+, CD4+/CD8+ and HIV-1 viral loads will be obtained&#xD;
      from HIV-1 positive participants every month for a period of six month. After 6 month of&#xD;
      prospective longitudinal survey, the first follow-up survey of the recruited study&#xD;
      participants will be conducted with the objective of determining prevalence and intensity of&#xD;
      human intestinal schistosomiasis and other helminth infections. Other infections will also be&#xD;
      examined, includes malaria and viral hepatitis. Furthermore, S. mansoni induced morbidity&#xD;
      will be examined using ultrasonography. A blood sample will also be obtained for all HIV-1&#xD;
      positive patients, from which CD4+, CD4+/CD8+ and HIV-1 viral loads will be examined. In the&#xD;
      same survey, individuals who tested HIV-1 negative at baseline will also be screened for HIV.&#xD;
      After the first follow-up survey, three groups will be formed, Group A- individuals&#xD;
      co-infected with HIV-1 and S. mansoni (N=270); Group B- individuals infected with HIV-1 but&#xD;
      S. mansoni negative (N=180) and Group C- HIV-1 negative but S. mansoni positive (N=1320)&#xD;
      (Figure 2). All individuals who will be infected with S. mansoni and other helminth detected&#xD;
      in the study irrespective of HIV-1 serostatus will be treated with praziquantel (40mg/kg) and&#xD;
      albendazole (400mg). At six to eight weeks after mass treatment, a second survey will be&#xD;
      conducted in the recruited participants aiming at determining cure rates of S. mansoni after&#xD;
      chemotherapy with praziquantel. The third survey will be conducted 12 month after the first&#xD;
      follow-up survey with the aim of determining the change in CD4+, CD4+/CD8+, HIV-1 viral&#xD;
      loads, HIV-1 progression and reversibility of the S. mansoni related liver morbidity after&#xD;
      praziquantel&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The impact of Praziquantel in HIV-1 individuals co-infected with Schistosoma mansoni</measure>
    <time_frame>12 month follow-up</time_frame>
    <description>Impact of praziquantel treatment on CD4+,CD4+/CD8+, HIV-1 viral loads haemoglobin level, reversibility of liver pathology and occurance of opportunistic infection&#xD;
Prevalence of co-infections of HIV-1 and Schistosoma mansoni&#xD;
Prospective longitudinal association between HIV-1 and S. mansoni, and the progression of HIV to AIDS, according to S. mansoni infection status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of praziquantel</measure>
    <time_frame>12 months</time_frame>
    <description>Cure rates&#xD;
Reductions of infections intensities</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Anemia</condition>
  <condition>Intestinal Helminthiasis</condition>
  <condition>Intestinal Schistosomiasis</condition>
  <condition>Human Immunodeficiency Virus I Infection</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Opportunistic Infections</condition>
  <arm_group>
    <arm_group_label>HIV-1 co-infected with schistosoma mansoni</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-1 patients co-infected with Schistosoma mansoni</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-1 positive individuals with negative S. mansoni</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HIV-1 positive individuals with negative Schistosoma mansoni</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schistosoma mansoni positive but HIV-1 negative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schistosoma mansoni positive individuals but HIV-1 negative to be compared with HIV-1 co-infected with Schistosoma mansoni individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-1 and Schistosoma mansoni negative</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Individuals with no HIV-1 and S. mansoni infections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praziquantel and Albendazole</intervention_name>
    <description>Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once</description>
    <arm_group_label>HIV-1 co-infected with schistosoma mansoni</arm_group_label>
    <other_name>DISTOCIDE</other_name>
    <other_name>ZENTEL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praziquantel and Albendazole</intervention_name>
    <description>Praziquantel- 40mg/kgBWT Albendazole - 400mg once</description>
    <arm_group_label>HIV-1 and Schistosoma mansoni negative</arm_group_label>
    <arm_group_label>HIV-1 co-infected with schistosoma mansoni</arm_group_label>
    <arm_group_label>HIV-1 positive individuals with negative S. mansoni</arm_group_label>
    <arm_group_label>Schistosoma mansoni positive but HIV-1 negative</arm_group_label>
    <other_name>DISTOCIDE</other_name>
    <other_name>ZENTEL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praziquantel and Albendazole</intervention_name>
    <description>Praziquantel- 40MG/KG ONCE Albendazole - 400mg once</description>
    <arm_group_label>HIV-1 co-infected with schistosoma mansoni</arm_group_label>
    <arm_group_label>HIV-1 positive individuals with negative S. mansoni</arm_group_label>
    <arm_group_label>Schistosoma mansoni positive but HIV-1 negative</arm_group_label>
    <other_name>DISTOCIDE</other_name>
    <other_name>ZENTEL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Permanent residents and those who have lived in the village for more than 2 years.&#xD;
&#xD;
          -  HIV-1 positive individuals only those with CD4+ â¥ 400 cells/Î¼l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-1 positive individuals with CD4+ &lt; 350 cells/Î¼l,&#xD;
&#xD;
          -  Those who are on antiretroviral therapy (ARV)&#xD;
&#xD;
          -  Pregnant women are excluded.&#xD;
&#xD;
          -  Participants with chronic diseases such as leukemia, tuberculosis and viral hepatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Humphrey D Mazigo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ilemela District</name>
      <address>
        <city>Mwanza</city>
        <state>Lake Victoria Zone</state>
        <zip>+255</zip>
        <country>Tanzania</country>
      </address>
    </facility>
    <investigator>
      <last_name>Humphrey D Mazigo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute for Medical Research, Mwanza</name>
      <address>
        <city>Mwanza</city>
        <state>Lake Victoria Zone</state>
        <zip>+255</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <last_update_submitted>March 2, 2012</last_update_submitted>
  <last_update_submitted_qc>March 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makerere University</investigator_affiliation>
    <investigator_full_name>Humphrey Mazigo, Msc, MPH</investigator_full_name>
    <investigator_title>Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma mansoni co-infections and its impact on anthelminthic treatment outcome among HIV-1 infected individuals in fishing communities in Mwanza region, Northwestern Tanzania.</investigator_title>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus-1</keyword>
  <keyword>Schistosoma mansoni</keyword>
  <keyword>Anemia</keyword>
  <keyword>Immune response</keyword>
  <keyword>Opportunistic infections</keyword>
  <keyword>Tanzania</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Opportunistic Infections</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>Schistosomiasis</mesh_term>
    <mesh_term>Helminthiasis</mesh_term>
    <mesh_term>Schistosomiasis mansoni</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

